As of November 14, 2026, Dermata Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 25, 2026, naming 1 departure. The latest filing names Mary Fisher, leaving (Form 8-K, February 25, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Dermata Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Dermata Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-25. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Dermata Therapeutics, Inc. files it.
Also on the record for Dermata Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Stake report, Schedule 13G, by Bigger Michael | 8.36% of the class | 5%+ stakes | Source |
| June 1, 2026 | Stake report, Schedule 13D, by Kyri K. Van Hoose | 9% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| April 22, 2026 | Stake report, Schedule 13G/A, by BIGGER CAPITAL FUND L P | 1.87% of the class | 5%+ stakes | Source |
| February 23, 2026 | Stake report, Schedule 13D/A, by PROEHL GERALD T | 17.3% of the class | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by Bigger Michael | 9.89% of the class | 5%+ stakes | Source |
| February 2, 2026 | Stake report, Schedule 13D/A, by PROEHL GERALD T | 19.6% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13D/A, by PROEHL GERALD T | 24.7% of the class | 5%+ stakes | Source |
| January 7, 2026 | Form D, private offering | $4.12M sold | Form D page | Source |
| January 2, 2026 | Stake report, Schedule 13G, by Mitchell P. Kopin | 5.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Dermata Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Dermata Therapeutics, Inc. and the records around it.
Dermata Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing Jan 2026
- Form D filing Jan 2026
- Who owns it
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: Neuraxis, INC (Nov 2026), ClearPoint Neuro, Inc. (Nov 2026), BTC Digital Ltd. (Oct 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: Elong Power Holding Limited (Nov 2026), 60 Degrees Pharmaceuticals, Inc. (Nov 2026), Bluejay Diagnostics, Inc. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Dermata Therapeutics, Inc.
Get an email when Dermata Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dermata Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dermata Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dermata Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-25 | Out | 8-K, 2026-02-25 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Mary Fisher (filed 2026-02-25):
Ms. Fisher's resignation was not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies or practices.
New leaders reset buying decisions — get the Full Report on Dermata Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Dermata Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Dermata Therapeutics, Inc.Every change, in the filing's words
Departing: Mary Fisher
Ms. Fisher resigned from the Board in order to comply with her employer recently being acquired and no longer permitting her to serve on the Company's Board.
- On February 23, 2026, Mary Fisher provided Dermata Therapeutics, Inc. (the "Company") with notice of her resignation from the Board of Directors (the "Board"), including from her role on any committees thereof, effective March 31, 2026.
Tools for this story
Each opens in a new tab, filled in for Dermata Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
